Novartis AG
NYSE:NVSDrug Manufacturers - General
-$3.38 today
- Market cap
- $293.13B
- Beta
- 0.49
- P/E (TTM)
- 20.7
- EPS (TTM)
- $7.06
- Dividend yield
- 3.13%
Volume 2.75M
Average 1.56M
NVS Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Novartis AGNYSE: NVS
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin declines year over year
Q2 FY2026 selling, general & admin of $3.24B fell 5.8% year over year, behind the -0.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 3.3% from the prior quarter. Over 3 fiscal years it compounded at +3.0% a year.
Context
- Selling, general & admin amounted to 24.3% of revenue in FY2025, unchanged from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 12 analysts of $15.09B (+13.4%) for the fiscal year ending Dec 2026, a step up from the +5.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $3.24B+3.3% QoQ
- Last fiscal yearDec 2025
- $13.31B+5.9% YoY
- LTMJun 2026
- $13.13B-0.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 13.31B USD
- Year-over-year change
- +5.9%
- 4-year CAGR
- +0.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.31B | +5.9% |
| FY2024 | 2024-12-31 | 12.57B | +0.4% |
| FY2023 | 2023-12-31 | 12.52B | +2.7% |
| FY2022 | 2022-12-31 | 12.19B | -4.9% |
| FY2021 | 2021-12-31 | 12.83B | — |
Selling, General & Admin vs competitors
How NVS compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -0.1% is the 8th highest of 11, against a peer median of +4.6%.
- Selling, general & admin amounts to 23.6% of revenue for NVS, versus a peer median of 21.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 64.84B DKK | -9.7% | +11.5% | 19.7% | |
| LTM Sep 2026 | $25.5B USD | +11.0% | +5.4% | 25.7% | |
| LTM Sep 2026 | $20.52B USD | +0.5% | +4.5% | 33.0% | |
| LTM Sep 2026 | $15.19B USD | +8.7% | -2.8% | 23.0% | |
| LTM Jun 2026 | $13.72B USD | -1.7% | +0.3% | 21.5% | |
| LTM Jun 2026 | $13.13B USD | -0.1% | +3.0% | 23.6% | |
| LTM Jun 2026 | $10.39B USD | +10.8% | +3.5% | 15.7% | |
| LTM Jun 2026 | €9.82B EUR | +9.8% | +5.4% | 20.1% | |
| LTM Jun 2026 | £9.2B GBP | -13.8% | +2.8% | 27.7% | |
| LTM Jun 2026 | $7.41B USD | -0.0% | -2.4% | 15.1% | |
| LTM Jun 2026 | $6.46B USD | +9.6% | +0.2% | 21.2% | |
| Peer median (excluding NVS) | — | +4.6% | +3.2% | 21.4% | |
Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 43.97B | 43.46B | 46.66B | 51.72B | 54.81B |
| Cost of Revenue | 11.74B | 11.58B | 12.47B | 12.83B | 13.69B |
| Gross Profit | 32.24B | 31.88B | 34.19B | 38.9B | 41.12B |
| Gross Margin | 73.3% | 73.4% | 73.3% | 75.2% | 75.0% |
| Research & Development | 8.64B | 9.17B | 11.37B | 10.02B | 10.74B |
| Selling, General & Admin | 12.83B | 12.19B | 12.52B | 12.57B | 13.31B |
| Operating Expenses | 22.18B | 23.93B | 24.42B | 24.35B | 24.05B |
| Depreciation & Amortization | 5.6B | 6.71B | 8.28B | 6.07B | 5.35B |
| EBITDA | 30.91B | 14.68B | 18.26B | 20.72B | 22.99B |
| EBITDA Margin | 70.3% | 33.8% | 39.1% | 40.1% | 41.9% |
| Operating Income | 10.06B | 7.95B | 9.77B | 14.54B | 17.07B |
| Operating Margin | 22.9% | 18.3% | 20.9% | 28.1% | 31.2% |
| Interest Income | 71M | 377.74M | 629.24M | 567.68M | 374.91M |
| Interest Expense | 905M | 834.62M | 876.12M | 1.04B | 1.19B |
| Other Income / Expenses | 14.47B | (769M) | (646M) | (904M) | (638.25M) |
| Income Before Tax | 24.53B | 7.18B | 9.12B | 13.64B | 16.44B |
| Pre-Tax Margin | 55.8% | 16.5% | 19.6% | 26.4% | 30.0% |
| Income Tax Expense | 1.63B | 1.13B | 551M | 1.7B | 2.4B |
| Net Income | 24.02B | 6.96B | 14.85B | 11.94B | 14.06B |
| Net Margin | 54.6% | 16.0% | 31.8% | 23.1% | 25.6% |
| EPS (Basic) | 10.71 | 3.19 | 7.15 | 5.92 | 7.25 |
| EPS (Diluted) | 10.63 | 3.17 | 7.10 | 5.87 | 7.19 |
| Weighted Avg Shares | 2.24B | 2.18B | 2.08B | 2.02B | 1.94B |
| Weighted Avg Shares (Diluted) | 2.26B | 2.2B | 2.09B | 2.04B | 1.96B |
Novartis AG
NYSE:NVS
Intrinsic Alpha fair value
Locked
Current Price
$155.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.